Tonix Pharmaceuticals announced it has entered into a securities purchase agreement with existing healthcare focused institutional investors of the Company for the purchase and sale of 14,666,666 shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to an aggregate of 14,666,666 shares of common stock in a registered direct offering at a combined offering price of $0.30 per share and accompanying warrant. The warrants have an exercise price of $0.33 per share, will be exercisable commencing six months from the date of issuance and will expire five and one-half years following the date of issuance. The closing of the offering is expected to take place on or about April 1, 2024, subject to the satisfaction of customary closing conditions. A.G.P./Alliance Global Partners is acting as sole placement agent for the offering.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNXP:
- Tonix Pharma Earns FDA Pediatric Designation Amid Risks
- Tonix Pharmaceuticals receives Rare Pediatric Disease designation for TNX-2900
- Tonix Pharma Reveals Innovative Oxytocin Research Advancements
- Tonix Pharmaceuticals announces presentation at ACS of next-gen oxytocin
- Tonix Pharma Readies for Tonmya™ U.S. Launch and Production